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0022-2836 © 2011 Elsevier Ltd. Open accGene expression during the intraerythrocytic development cycle of the
human malarial parasite Plasmodium falciparum is subject to tight temporal
control, resulting in a cascade of gene expression to meet the physiological
demands of growth, replication, and reinvasion. The roles of the different
molecular mechanisms that drive this temporal program of gene expression
are poorly understood. Here we report the use of the bxb1 integrase system
to reconstitute all aspects of the absolute and temporal control of the
prototypical housekeeping gene encoding the proliferating cell nuclear
antigen (Pfpcna) around an integrated luciferase reporter cassette. A
quantitative analysis of the effect of the serial deletion of 5′ and 3′ genetic
elements and sublethal doses of histone deacetylase inhibitors demonstrates
that while the absolute control of gene expression could be perturbed, no
effect on the temporal control of gene expression was observed. These data
provide support for a novel model for the temporal control of potentially
hundreds of genes during the intraerythrocytic development of this
important human pathogen.© 2011 Elsevier Ltd. Open access under CC BY license.Introduction
Plasmodium falciparum is the etiological agent of
the most pernicious form of human malaria, a
disease that exerts a massive toll on global health,
with some 1 million deaths resulting from 247Science and
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ess under CC BY license.million cases reported annually.1 Following the
publication of this organism's genome in 2002,2
major inroads have been achieved in our under-
standing of this parasite's complex biology in both
its human host and the anopheline mosquito vector,
as well as in describing its pathology at the
molecular level.3 That said, challenges in the
maintenance of an effective drug pipeline and
vaccine development underpin the importance of
translating this knowledge into an effective control
of this pathogen.4,5
The life cycle of P. falciparum is characterized by its
constant adaptation to diverse environments and a
strict programofmorphological development—with
evidence from high-throughput microarray and
proteomic analyses indicating that these phenomena
are underpinned by a global coordinated pattern of
developmentally linked gene expression.6–8 This is
perhaps best evidenced by the demonstration of a
206 Gene Expression in P. falciparumtightly coordinated cascade of coordinated gene
expression during the intraerythrocytic develop-
ment cycle (IDC)6—a stage of parasite development
that is readily accessible through in vitro culture but
is also key given that this is the stage of the life cycle
that is primarily responsible for the etiology of
disease. These data initially suggested a predomi-
nant role for cis–trans interactions in directing the
temporal control of gene expression, and since this
was presumably mediated at the level of transcrip-
tion initiation, this led to the so-called “transcript-to-
go” hypothesis.6,9 Subsequent analyses, however,
correlating steady-state mRNA levels with peptide
profiles have failed to provide proof for this
hypothesis.9–11 More recently, evidence for develop-
mentally linked mRNA stability, translational re-
pression, and noncoding RNA all suggest that while
cis–trans-directed promoter activity may play a
major role in the temporal control of gene expression,
other molecular mechanisms may equally impact on
this process.12–18
That said, understanding the contributions that
cis–trans interactions in gene flanking sequences
make in directing the temporal control of gene
expression is of fundamental importance. Early
functional data, using transfected reporter con-
structs, have proven to be key in demonstrating the
canonical nature of the P. falciparum promoter.19–24
Like other eukaryotes, P. falciparum promoters are
bipartite in nature, where RNA-polymerase-II-me-
diated transcription from a transcription start site
located in a minimal promoter region is directed by
cis–trans interactions in flanking sequences.16,18
While these studies have proven invaluable in
demonstrating a role for these cis–trans interactions
in directing the absolute level of transcription, they
have proven less so in understanding their role in the
temporal control of transcription. This, in general,
can be attributed to two aspects of the experimental
approaches adopted. The first aspect is the reliance of
the reporter constructs on transient transfection; in
the absence of drug pressure, plasmids are rapidly
lost from the parasite.25,26 Moreover, the absence of
nucleosome assembly over these plasmids results in
what appears to be a constitutive expression of the
reporter gene.26 Stable episomal transfection over-
comes this limitation, as these drug-selected plas-
mids assemble nucleosomes during S-phase.27,28
Using this approach, however, is problematic from
a quantitative viewpoint, as these plasmids often
concatamerize and show evidence of unequal
segregation during mitotic division.25 This experi-
mental approach has, however, shown in a small
number of cases that appropriate temporal control
can be reconstituted for a reporter gene.29–32 The
mixed success for this approach may be attributed to
a second aspect of the approaches adopted: the mix
and match of 5′ and 3′ flanking sequences from
different genes. Given the potential for both 5′ and 3′sequences working together to contribute to the
temporal regulation of gene expression, this practice
may confound any sensible analysis of their relative
contributions.
The development of the bxb1 integrase-mediated
transfection system in P. falciparum offers an attrac-
tive tool to overcome some of these limitations.33
In this system, it is claimed that homogeneous
populations of genetically modified parasites,
each bearing a single chromosomally integrated
reporter construct, can be rapidly generated.33–35
To this end, we set out here to establish whether
such an experimental approach can be adopted to
reconstitute the correct temporal control of expres-
sion for a luciferase construct from the matched
5′ and 3′ flanking sequences of a P. falciparum
gene.
The gene selected for this study was Pfpcna
(Pf13_0328). This gene encodes the proliferating
cell nuclear antigen, a key processivity factor for
DNA polymeraseΔ on the leading strand, accessory
roles in DNA replication/repair and maintenance of
epigenetic marks during mitosis.21,36,37 Three factors
directed its choice in this study. First, Pfpcna has a
known pattern of temporal expression during the
IDC; the transcript and protein steady-state levels
peak in mature trophozoites, coinciding with the
known demand for DNA synthesis.36 Second,
previous studies have characterized the minimal
promoter (including mapping of the transcription
start site) and have demonstrated (using a transient
transfection system) a role for flanking sequences in
directing the absolute level of gene expression.21
Third, and perhaps most importantly, Pfpcna repre-
sents an excellent candidate for a prototypical
housekeeping gene under coordinated temporal
control during the IDC. Pfpcna transcription shares
a temporal pattern with over 30 genes known to be
involved in DNA replication and metabolism—and
more widely with several hundred genes upregu-
lated in expression during the metabolically active
trophozoite stage.6,38 Over recent years, some
excellent work on the control of expression of the
different members of the var multigene family has
been performed—work that reflects the importance
of their gene products in the pathology of infected
erythrocytes (for reviews, see Llinás et al.,18 Dzi-
kowski and Deitsch,39 Scherf et al.,40 and Chooka-
jorn et al.41). However, the temporal control of
expression of var genes during the IDC is overlaid
by a complex layer of control that ensures that only
one member of this multigene family is expressed in
each parasite and is therefore not typical of the
control of the vast majority of the genome.
Here we describe an analysis of the genetic and
epigenetic factors that govern the absolute and
temporal control of a P. falciparum prototypical
housekeeping gene in an attempt to describe
the molecular mechanisms that govern the
207Gene Expression in P. falciparumcontrol of gene expression in this important human
pathogen.Results
Reconstitution of the correct temporal profile
of Pfpcna expression on an integrated
luciferase cassette
The IDC for P. falciparum takes 48 h and is
characterized by progression through a series of
morphologically distinct stages: ring [0–16 h post-
infection (hpi)], trophozoite (17–38 hpi), and schiz-
ont (39–48 hpi). Pfpcna shows a coincident temporal
profile of mRNA and protein steady-state levels
during the IDC, starting low in rings, peaking in
mature trophozoites to meet the demands of DNA
synthesis at this stage, and subsiding again in
schizonts.6,21 Our initial aim was to demonstrate
that sufficient Pfpcna 5′ and 3′ flanking sequences
were used to reconstitute this same temporal pattern
of expression for a luciferase reporter cassette
integrated into the parasite's genome.
The plasmid pΔ1 contains a luciferase reporter
gene flanked by 1418 bp and 647 bp of 5′ and 3′
Pfpcna sequences, respectively, in a pDCattP
backbone to facilitate integration into the genome
of the P. falciparum clone AHEI.33 In this parasite
clone, the attB site for the mycobacteriophage
bxb1's integration into Mycobacterium smegmatis
has been inserted into the cg6 locus on chromo-
some 7. Using established transfection and drug
selection procedures,33 we derived two indepen-
dent clones, Δ1.1 and Δ1.2. Successful integration
of a single copy of pΔ1 into the correct locus was
confirmed by PCR over the attL site, generated
following cross-over recombination between the
attP site and the attB site, as well as Southern blot
analysis (Fig. 1a–c).
In order to demonstrate the reconstitution of the
correct temporal profile of expression, we carried
out serial Northern blot and luciferase assays
throughout the IDC. Harvest of RNA and cyto-
plasmic protein fractions was carried out at the T1
(ring, 6–12 hpi), T2 (early trophozoite, 18–24 hpi),
T3 (mature trophozoite, 30–36 hpi), and T4
(schizont, 40–46 hpi) time points. Inspection of
parasite morphology on Giemsa-stained thin blood
film by light microscopy confirmed the presence of
at least 80% of the appropriate stage in each time
point. The expected temporal pattern of Pfpcna
steady-state mRNA levels was observed for the
endogenous gene, with transcripts of 1.8 kb and
2.2 kb peaking in level at the T3 (late trophozoite)
sample (Fig. 1d).36 The luciferase steady-state
mRNA levels show a very similar temporal profile,
with the peak of expression at T3 (late trophozo-ite), albeit with transcript sizes of 2.6 kb and 3 kb
(Fig. 1d). In order to quantitatively describe the
temporal profile, we captured and normalized the
signal intensity of the paired transcripts at each
stage as a percentage of the peak signal in T3 (Fig.
1e). Comparison of the normalized transcript
intensities clearly demonstrates a successful recon-
stitution of the correct temporal mRNA steady-
state levels for luciferase during the IDC. Com-
parison of the results of the luciferase reporter
assays at the equivalent T1–T4 time points
similarly demonstrates the reconstitution of a
coincident temporal profile of luciferase activity
with the expected peak of activity at the T3 late
trophozoite stage (Fig. 1f).
The difference in sizes between the transcripts
obtained for Pfpcna and the transcripts obtained
for luciferase (Fig. 1d) was approximately 800 bp,
the same difference in size between the open
reading frames for the two genes. This would
suggest that the transcriptional apparatus recog-
nizes the same transcriptional start and polyade-
nylation sites in the Pfpcna 5′ and 3′ flanking
sequences around both the endogenous version
and the integrated version of these sequences.
Pfpcna has a major transcription start site located
960 bp upstream of the open reading frame.21 The
transcription start site for the luciferase transcript
was mapped using 5′ rapid amplification of cDNA
ends (RACE), and ClustalN analysis of the five
independent clones derived indicated that four of
the clones absolutely correlated with the previous-
ly mapped Pfpcna transcription start site with the
last clone's sequence, including an additional eight
bases of 5′ sequence (Fig. S1). Due to the lack of
information regarding the position of the Pfpcna
polyadenylation site, 3′ RACE was carried out for
both the Pfpcna transcript and the luciferase
transcript (Fig. S1). A total of 16 clones were
generated: 11 were derived from the luciferase
transcript, and 5 were derived from the Pfpcna
transcript. ClustalN analysis revealed two major
polyadenylation sites and one minor polyadenyla-
tion site. The two major sites (+161 bp and
+252 bp from the open reading frame) are
apparently utilized by both the Pfpcna transcript
and the luciferase transcript. The minor site
(+216 bp) was utilized only by the Pfpcna
transcript. All three sites are positioned adjacent
to a 5′-AATAA-3′ sequence located 10–30 nucleo-
tides upstream of U/GU-rich regions, features
predicted to be the consensus sequence for the
site of polyadenylation in Plasmodium spp.42,43
Together, these data indicate that the luciferase
transcript from pΔ1 utilizes the Pfpcna 5′ and 3′
flanking sequences in determining the limits of the
transcript, as well as the absolute and temporal
patterns of expression in the same way that these
flanking sequences act for the endogenous gene.
Fig. 1. Reconstitution of the correct temporal and absolute control of Pfpcna expression in the Δ1 integrant. (a) Site-
specific integration of the pΔ series of plasmids into the attB–cg6 locus of the parasite clone AHE1 facilitated by bxb1
integrase (Int) on pINT. The position of the oligonucleotide probes and the region amplified over the attL locus are
indicated by inverted arrows and the dotted line. EV, EcoRV restriction site; BSD, blasticidin S deaminase selectable
marker; dhfr, human dihydrofolate reductase selectable marker; Neo, neomycin selectable marker. This figure was
adapted fromNkrumah et al.33 (b) Southern blot analysis of 10 μg of genomic DNA restricted with EcoRV fromAHE1 and
Δ1 and sequentially hybridized with probes to cg6 and dhfr. Fragment sizes are indicated in kilobases (kb). (c) PCR
confirmation of integration in Δ1 by amplification of a 1.88-kb fragment over the attL locus generated by a recombination
of attB and attP sites. PCR over 440 bp of dhfr acts as control for the maintenance of this site in AHE1. (d) Time-course (T1,
ring; T2, early trophozoite; T3, mature trophozoite; T4, schizont) Northern blot analysis of 10 μg of total RNA isolated
from Δ1 sequentially hybridized with probes to Pfpcna and luciferase genes. (e) Normalization of T1–T4 Northern blot
signal intensities for luciferase and Pfpcna to signal intensity at T3. (f) Time-course luciferase activity assay data for Δ1
expressed as relative light units (RLU) per 1×107 infected red blood cells (irbc). Data represent the mean and standard
error of the mean of five independent paired measurements from clones Δ1.1 and Δ1.2.
Fig. 2. Analysis of absolute and temporal luciferase expressions in 5′ and 3′ Pfpcna serial deletion constructs. (a) Time-
course (T1, ring; T2, early trophozoite; T3, mature trophozoite/schizont) Northern blot analysis of 10 μg of total RNA
isolated from the 5′ deletion series (Δ1-ΔKO) sequentially hybridized with probes to Pfpcna and luciferase genes.
Transcript sizes are indicated in kilobases (kb). T3 luciferase signal intensities are normalized against matched T3 Pfpcna
signal intensity and plotted as a proportion of this ratio in Δ1. (b) The first two panels represent time-course (T1–T3)
Northern blot analysis of the 3′ deletion series constructs that were successfully integrated (Δ4 and Δ5) and sequentially
hybridized with probes to Pfpcna and luciferase genes. Mixed (M)-stage total RNA of integrants Δ6 and Δ7 shows the
absence of any luciferase transcript signal. (c) The left-hand panel shows the 5′ and 3′ Pfpcna flanking sequences around
the luciferase reporter cassette for each of the Δ series clones used in this study. Transcription start and polyadenylation
sites are indicated with an arrow and a lollipop, respectively. A (ApaI) and P (PstI) restriction sites flank the reporter
cassette. The right-hand panel indicates time-course (T1, ring; T2, early trophozoite; T3, mature trophozoite/schizont)
luciferase activity assay data for the Δ series expressed as relative light units (RLU) per 1×107 infected red blood cells
(irbc). Data represent the mean and standard error of the mean of at least five independent paired measurements.
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demonstrate an effect on the absolute, but not
temporal, control of Pfpcna expression
Previous analysis of the 5′ flanking sequences of
Pfpcna mapped a core promoter region (−710 bp toFig. 2 (legend on t−1180 bp) and a putative enhancer region (−1250 bp
to −1580 bp).21 In order to better delineate
sequences in the 5′ and 3′ Pfpcna flanking regions
that direct the control of both absolute expression
and temporal expression, we prepared a series of
deletion constructs based on pΔ1 (Fig. 2; Fig. S2) andhe previous page)
210 Gene Expression in P. falciparumtransfected them into the AHEI clone. As described
above, PCR and Southern blot analysis of the
resultant transfectants were carried out to demon-
strate a correct integration into the cg6 locus (Fig.
S3). This analysis confirmed the correct integration
of pΔ2, pΔ3, pΔ4, and pΔ5, with the remaining
constructs (pΔKO, pΔ6, and pΔ7) apparently only
maintained episomally as concatamerized plasmid
despite four independent attempts at integration.
Thus, while these luciferase reporter constructs were
present in the parasite, data developed from
subsequent luciferase activity assays are only
described qualitatively, as they were deemed not
equivalent to those transfectants where the plasmid
had integrated into chromosome 7.
Northern blot and luciferase reporter assays of
samples collected at three time points during the
IDC were carried out: T1, ring (6–12 hpi); T2, early
trophozoite (18–24 hpi); T3, mature trophozoite/
schizont (30–40 hpi). For all the 5′ transfectant clones
and for the two 3′ integrated clones, the correct
absolute and temporal patterns of Pfpcna steady-
state mRNA accumulation were observed, with the
expected peak in level observed in the mature
trophozoite/schizont (T3) stages (Fig. 2a and b).
The steady-state mRNA levels for luciferase in Δ2,
Δ3, ΔKO, Δ4, and Δ5 clearly mimicked this
temporal pattern of gene expression, although
there was a notable decrease in the absolute level
of luciferase transcript as increasing increments of
the 5′ flanking sequence were deleted (Fig. 2a).
Normalizing the T3 luciferase transcript signal
against matched Pfpcna transcript signal intensity
allowed the overall effect of 5′ sequence deletion on
the steady-state level of luciferase mRNA accumu-
lation to be compared to Δ1, with apparent
reductions of 28%, 43%, and 96% for Δ2, Δ3, and
ΔKO, respectively. For the 3′ flanking series, there
appeared to be a distinct “all-or-nothing effect” (Fig.
2b). Steady-state luciferase transcript levels
remained essentially unchanged from that of Δ1 in
transfectants Δ4 and Δ5, both containing the
mapped polyadenylation sites, while deletion of
these sites in transfectants Δ6 and Δ7 yielded no
observable luciferase transcript.
As expected from the Northern blot data, the
maximal peak in luciferase activity was reported in
the mature trophozoite/schizont (T3) stage for Δ1,
Δ2,Δ3,Δ4, andΔ5 (Fig. 2c). TransfectantsΔKO,Δ6,
and Δ7 had no luciferase activity above background
levels in any of the time points assayed, emphasiz-
ing the key role for the mapped transcription start
and polyadenylation sites that are missing in these
constructs. While deletions in the 5′ series (Δ2 and
Δ3) were accompanied by stepped reductions in the
absolute level of luciferase activity in T3 (by 48%
and 75%, respectively), no apparent difference was
observed at the same time point in the 3′ series (Δ4
andΔ5) when compared toΔ1. One-way analysis ofvariants of the reduced luciferase activities in the 5′
deletion series revealed no significant differences in
the T1 and T2 time points (p=0.525 and p=0.307,
respectively), while a significant difference was
observed at the T3 stage (p=0.004), with the
significant difference being found between Δ1 and
Δ3 using Tukey's posttests. All tests for significance
between Δ1 and the 3′ series (Δ4 and Δ5) at all time
points were insignificant.
Nuclear factors bind regions demonstrated to
function in Pfpcna promoter activity
The Pfpcna promoter assays demonstrated the
presence of two putative enhancer regions
(−1418 bp to −1201 bp, and −1200 bp to −1031 bp)
upstream of a newly refined minimal promoter
region (−1030 bp to −840 bp). To explore the
potential for nuclear trans-acting factor binding to
the distal 5′ flanking regions identified, we gener-
ated a tiling path of 11 minimally overlapping 50–
60mer double-stranded oligonucleotides (here
termed probes) (Fig. 3a) and subjected it to
electrophoretic mobility shift assays (EMSAs) with
nuclear extracts from trophozoite-stage parasites.
As control, PfTBP, a probe containing the TATA
binding protein (TBP) binding site in the minimal
promoter of gbp130 (PF10_0159), was included in the
analysis.44 To demonstrate the specificity of each
interaction, we repeated the EMSAs with a 200-fold
molar excess of homologous unlabeled probe to
ensure complete ablation of any cis–trans interac-
tions observed. Probes 2, 3, 6, 7, 8, 9, and 10 all
showed evidence of nuclear factor(s) binding—a
pattern of interactions suggesting that trans-acting
factors bind to the most distal enhancer element and
the entire minimal promoter region (Fig. 3b).
To demonstrate a specific and titratable effect
typical of a true cis–trans interaction, we took
forward the gbp130 probe and probes 2, 3, and 7
for a more complete competition assay. The latter
probes were chosen as (i) they gave strong, readily
reproducible evidence of complex formation com-
parable to the control, and (ii) the complex formed
was completely ablated upon competition with an
excess of unlabeled homologous probe. Trophozoite
nuclear extracts were preincubated with increasing
molar excess of unlabeled homologous or nonho-
mologous (random sequence) probes before the
addition of the labeled probe. The signal intensity
of the bound complex was then determined as a
proportion of the signal in the absence of any
competition (Fig. 4). In all cases, titratable inhibition
of complex formation was demonstrated using the
homologous probe, with the specificity of this
interaction shown by the absence of a comparable
effect using increasing molar excess of the nonho-
mologous probe. Given that probes 2 and 3 are
located within the same putative enhancer element
Fig. 3. EMSA of distal 5′ Pfpcna flanking sequence. (a) A minimally overlapping tiling path of eleven 50–60mer double-
stranded oligonucleotide probes covers the regions functionally analyzed in the promoter assay (see Table S1 for exact
positions). The sites for the start of each clone (Δ1-ΔKO) are indicated with an annotation of the predicted function of the
intermittent DNA sequences. Successful specific interaction with a nuclear extract is indicated by a ticked box below each
probe. (b) EMSA showing free probe (−), probe with 5 μg of nuclear extract (+), or the same with a 200 molar excess of
unlabeled homologous probe (C). The positions of the free probe (FP) and the complexed probe (CP) are indicated as is the
probe used in each EMSA.
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comparable regions within their respective minimal
promoters, cross-competition assays were carried
out with these pairs of probes. The complexes
formed by probes 2 and 3 were effectively competed
by a 100 molar excess of both the homologous probe
and the corresponding nonhomologous probe (Fig.
S4), suggesting that the same trans-acting factor
binds probes 2 and 3. Similarly, probe 7 complex
formation was abolished by the addition of a
100 molar excess of the gbp130 probe (Fig. S4).
Probe 7 lies between 37 bp and 93 bp upstream of
the mapped transcription start site, a position
comparable to that demonstrated for gbp130 and
kahrp (PFB0100c), the site of preinitiation complex
formation over the minimal promoter region.44 The
design of probe 7 was refined to give a probe lying
between 40 bp and 80 bp upstream of the
transcription start site entirely within the mapped
minimal promoter for Pfpcna. This new probe,
designated probe 7a, was shown to bind the
trophozoite nuclear protein(s), with the interaction
being both specific and titratable (Fig. 5a). A series of
mutations was introduced into this sequence to give
probes 7b, 7c, and 7d (Fig. 5b). These mutations
targeted two sequences shown by sequence com-
parison to share a level of homology to the cis-acting
binding site for TBP and a novel motif (PM29.2)
identified in in silico studies of overrepresented
motifs in P. falciparum gene flanking sequences.44,45
Increasing molar excess of these unlabeled mutated
probes was used to establish their potential toinhibit the interaction of probe 7a with trophozo-
ite-stage nuclear protein(s) (Fig. 5c). While some
reduction in the signal intensity of the bound
complex formed in the presence of probe 7b was
observed, this effect was clearly not titratable, with
evidence of complex formation still evident on the
addition of a 100-fold molar excess of unlabeled
probe. A high molar excess of probe 7c, however,
appears to considerably reduce probe 7a complex
formation—an interesting observation as the muta-
tions introduce a cryptic consensus PfTBP recogni-
tion site. Mutation of this cryptic site in probe 7d
appears to restore probe 7a complex formation in
the presence of a 100-fold molar excess of this
unlabeled heterologous probe.
Sublethal doses of histone deacetylase
inhibitors do not release the temporal inhibition
of Pfpcna expression in ring-stage parasites
Type I/II histone deacetylase (HDAC) inhibitors
have been demonstrated to rapidly induce a
profound dysregulation of the tight temporal
control of transcription in the IDC, with evidence
of histone hyperacetylation, morphological changes
typical of programmed cell death (PCD), and delay
in IDC progression with failure to reinvade.46–50
Here we explore the use of sublethal doses of two
related HDAC inhibitors—suberoylanilide hydro-
xamic acid (SAHA) and suberohydroxamic acid
(SBHA)—to determine their effect on the absolute
and temporal expressions of luciferase in the Δ1
Fig. 4. Specific and titratable cis–
trans interactions in the distal 5′
regions of the Pfpcna promoter. The
left-hand panels show EMSA with
probes 2, 3, and 7 of Pfpcna and the
gbp130 positive control alone
(probe), or with 5 μg of trophozo-
ite-stage nuclear extract (complex)
and the indicated increasing-fold
molar excess of homologous or
heterologous random unlabeled
probe. The intensity of the indicated
complex formed in each lane is
plotted as a proportion of the signal
in the absence of any homologous
(black circles) or heterologous
(open circles) competitors in the
right-hand panels.
212 Gene Expression in P. falciparumtransfectant, in particular whether the temporal
repression of luciferase expression in ring-stage
parasites can be lifted.
Dose–response curves for SAHA and SBHA
inhibition of parasite growth were determined
using the 3D7 parasite strain, with IC50 values of
1.43±1.03 μM and 8.06±1.08 μM for SAHA and
SBHA, respectively, comparable to previously pub-
lished results.46,47 Preliminary time-course experi-
ments using concentrations of drugs comparable to
IC2 and IC5–7 demonstrated that both SAHA
(0.05 μM and 0.5 μM) and SBHA (1.2 μM and
2.2 μM) induce time-dependent and concentration-
dependent effects on parasite progression through
the IDC, while not significantly decreasing para-sitemia over 48 h of drug exposure (data not shown).
Parasite cultures tightly synchronized to early rings
(0–6 hpi) were exposed to both drugs at both
concentrations, with samples taken at T1 (ring, 10–
16 hpi), T2 (trophozoite, 22–28 hpi), T3 (mature
trophozoite/schizont, 34–42 hpi), and T4 (schizont/
early ring, 44–6 hpi) through, and onto the next, IDC
for assessment of parasitemia, parasite staging, and
luciferase activity.
For SAHA, assessment of parasite staging showed
no significant difference in the relative proportion of
each morphological stage during the first 24 h of
drug treatment (T1 and T2) compared to the control
without drug (Fig. 6a). From 24 h, however, we
observed a significant difference in the relative
Fig. 5. EMSA of modified probe 7. (a) The left-hand panels show EMSA with probe 7a alone (probe) or with 5 μg of
trophozoite-stage nuclear extract (complex) and increasing-fold molar excess of homologous or heterologous random
unlabeled probe. The intensity of the indicated complex formed in each lane is plotted as a proportion of the signal in the
absence of any homologous (black circles) or heterologous (open circles) competitors on the right-hand graph. (b)
Comparison of the sequence of probe 7 (top line) with the minimally refined probe 7a and versions thereof introducing
site-specific mutations (in boldface) in the underlined sequences of interest. Sequence TCCCACA is the reverse
complement of TGTGGGA, a variant of motif PM29.2,45 with the cryptic TATA box introduced in probe 7c highlighted in
gray. (c) Competition EMSA for probe 7a complex formation in the presence of an increasing-fold molar excess of mutated
probes 7b, 7c, and 7d. The intensity of the complex formed in each lane is plotted as a proportion of the signal in the
absence of any competitor (probe alone). Probe 7b (inverted triangle), probe 7c (square), and probe 7d (triangle).
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Fig. 6. Treatment of Δ1 with sublethal doses of SAHA. (a) The mean proportion of each IDC morphological stage at
each harvest time point (T1, ring; T2, early trophozoite; T3, mature trophozoite; T4, schizont in untreated control) during
the time course of treatment with either 0.05 μMor 0.5 μMSAHA or the untreated control. (b) Dunett's test for proportions
to determine significant differences (qN2.21) for the proportion of each morphological stage (R, ring; T, trophozoite; S,
schizont) in drug-treated parasites (0.05 μM or 0.5 μM SAHA) compared to the untreated control. q values of N+2.21 and
b−2.21 (dotted lines) represent a significant decrease or increase in that morphological stage, respectively. (c) Mean and
standard error of the mean of the parasitemia of untreated control and SAHA-treated cultures during the time course of
the study. (d) Time-course luciferase activity assay data for untreated control and SAHA-treated Δ1 expressed as relative
light units (RLU) ×105 per 1×107 infected red blood cells (irbc). Data represent the mean and standard error of the mean of
five independent paired measurements.
214 Gene Expression in P. falciparumproportion of the different morphological stages in
T3 and T4 that increases with both time of exposure
and drug concentration, apparently revealing a
delay in progression of the IDC (Fig. 6b). This is
exemplified by the significant reduction in the
proportion of rings in T4 using 0.5 μM SAHA
(IC5), with schizonts instead representing the pre-
dominant developmental stage present, supporting
the evidence for no increase in parasitemia due to
the failure to complete the IDC (Fig. 6c). Luciferase
activity in the control cultures peaked, as expected,
in T3 (mature trophozoite/schizont). Luciferase
activity upon treatment with 0.5 μM SAHA is
significantly reduced in T3 (p=0.01), with lower
levels also observed for treatment with 0.05 μM (IC2)
SAHA and with levels of luciferase activity for bothtreatments higher than the control at T4 (Fig. 6d).
The apparent shift in the peak of luciferase activity
for SAHA-treated parasites correlates with the
relative effect of the dose of the drug on parasite
progression (i.e., the higher the dose of SAHA, the
more pronounced is the delay in IDC, which then
results in a greater shift in the peak of luciferase
activity to the next time point in the harvest). Thus,
while SAHA appears to alter the absolute pattern of
temporal luciferase activity during T1–T4, the
underlying effect of SAHA on the IDC means that
the observed peak of luciferase activity in all
samples is still maintained in the mature trophozo-
ite/schizont stages. Importantly, for both concen-
trations of SAHA, there is no apparent induction of
luciferase expression in ring-stage parasites.
215Gene Expression in P. falciparumTreatment of parasite cultures with 1.2 μM and
2.2 μM SBHA, corresponding to IC2 and IC7,
respectively, similarly demonstrates time-depen-
dent and dose-dependent effects on IDC progres-
sion (Fig. S5). Again, the peak of luciferase activity is
maintained in the mature trophozoite/schizont
stage, with no evidence of induction of luciferase
expression in ring-stage parasites.
We reasoned that the apparent lack of induction of
luciferase expression in ring-stage parasites may
result either from a delay in the effect of the
sublethal doses of SAHA and SBHA within 24 h
and/or from histone marks being “hard-wired”
after being established in the previous cycle of the
IDC. The latter supposition is supported by evi-
dence indicating that commitment to sexual devel-Fig. 7. Treatment ofΔ1 with sublethal doses of SAHA and S
each IDCmorphological stage at each harvest time point (start,
two different concentrations of SAHA and SBHA. (b) Dunett
(qN2.21) in the proportion of each morphological stage (R, ring
key) compared to the untreated control. See also the legend to F
increase in the parasitemia (compared to start) of untreated c
course of the study. (d) Time-course luciferase activity assay
expressed as relative light units (RLU) ×105 per 1×107 infe
standard error of the mean of five independent paired measuopment is made in a prior cycle of the IDC and by
evidence of epigenetic “tagging” of the active
variant of the var multigene family being expressed
in a subsequent IDC.51,52 To this end, we carried out
a second time-course analysis where SAHA and
SBHAwere added tomature trophozoites/schizonts
and harvests were taken at two time points (+24 h
and +48 h) in the subsequent IDC.
The untreated control cultures showed the
expected temporal pattern of morphological devel-
opment with a 2-fold to 3-fold increase in para-
sitemia upon reinvasion (Fig. 7a–c). The luciferase
activity peaked at the +48 h time point in mature
trophozoites/schizonts, with the increase in activity
corresponding to the observed increase in parasite-
mia (Fig. 7c and d). The SAHA-treated and SBHA-BHA in a previous cycle of IDC. (a) Themean proportion of
+24 h, and +48 h) during the time course of treatment with
's test for proportions to determine significant differences
; T, trophozoite; S, schizont) in drug-treated parasites (see
ig. 6b. (c) Mean and standard error of the mean of the fold
ontrol and SAHA/SBHA-treated cultures during the time
data for untreated control and SAHA/SBHA-treated Δ1
cted red blood cells (irbc). Data represent the mean and
rements.
216 Gene Expression in P. falciparumtreated cultures both show dose-dependent and
time-dependent effects on the relative proportion of
staging, replicating the previously described delay
in IDC progression (Fig. 7a). Untreated cultures
mature normally, with a small proportion undergo-
ing a second round of reinvasion, as evidenced by
the fold increase in parasitemia and the increased
proportion of rings at +48 h (Fig. 7c). Except for the
higher dose of SAHA treatment, cultures subjected
to drug treatments showed an increase in para-
sitemia over 24 h, although at a rate lower than that
of the untreated control, but did not undergo a
second round of invasion and remained predomi-
nantly in the mature stages of parasite development.
The luciferase activities for the IC2-treated cultures
were higher in the 48-h time point, although at a
lower level than the control. This presumably
reflects reduced parasite numbers and PCD, as
evidenced by the poor morphology of these mature
parasites at between 30% and 60% (SAHA, 35±5%;
SBHA, 51±9%) (Fig. S6). The higher dose treatment
of both drugs significantly decreased luciferase
activities (p=0.01) at +48 h, again reflecting a
significant reduction in parasitemia (p=0.01) and
an increase in the proportion of mature intraery-
throcytic parasites with poor morphology to be-
tween 52% and 74% (SAHA, 63±11%; SBHA, 65
±7%) . In all cases, however, irrespective of the drug
or concentration applied, we were unable to induce
luciferase expression in ring-stage parasites.Discussion
Here we have described perhaps the most
complete study in P. falciparum that investigates
the molecular mechanisms that control the absolute
and temporal control of a prototypical housekeep-
ing gene during intraerythrocytic development.
Using 1418 bp and 647 bp of matching 5′ and 3′
flanking sequences from Pfpcna, we were able to
reconstitute all aspects of the control of gene
expression for an integrated luciferase reporter
gene, emphasizing this approach in developing
best practices in investigating gene expression in P.
falciparum. Reconstituting the correct absolute and
temporal patterns of mRNA and protein expression,
as well as the 5′ and 3′ limits of the luciferase
transcript in the Δ1 integrant, indicates that this
parasite represents amodel for the molecular control
of expression for an integrated reporter cassette
directly analogous to that of the endogenous gene.
Using this system, we were able to refine the
minimal promoter region and to additionally
characterize two putative 5′ distal enhancer ele-
ments, as well as to describe specific and titratable
nuclear trans-acting factor interactions with these
elements. Analysis of the sequences of the probes
used in the EMSA study reveals three interestingfindings. First, probe 7, which lies within the
minimal promoter region, potentially contains a
cis-acting element for the TBP of the TFIID
complex.44,53,54 Specific annotation of the TATAA
motif in P. falciparum is difficult given the extreme
AT bias of intergenic sequences, often in excess of
90%.2 However, functional evidence for binding
was suggested initially by the TBP binding site of
gbp130 effectively competing with probe 7 complex
formation and was then strengthened further when
introduction of a cryptic TBP site in probe 7c led to
effective competition of probe 7a complex formation—
an effect that was ablated when the cryptic site was
mutated in probe 7d. Second, probe 7 also contains
a putative PM29.2 motif (TGTGTGA) in the form of
TGTGGGA, a motif found to be significantly
overrepresented in the 5′ flanking sequences of
genes sharing the same temporal pattern of Pfpcna
expression and/or Gene Ontology annotation in the
replisome.45,55,56 Mutation of this motif in probes 7b
and 7d could not effectively compete with probe 7a
formation at a 100 molar excess, although a specific
titratable effect was difficult to achieve, as probe 7a
presumably interacts with more than one trans-
acting factor. The third finding was the identifica-
tion of a novel putative cis-acting sequence, TGAA
(AT)(AT)GG, present as a single copy in each of
probes 2 and 3, although inverted with respect to
one another. While novel, the evidence that probes 2
and 3 can effectively compete with the formation of
the other's complex and that both probes lie within
the same putative enhancer region responsible for
some 50% of promoter activity do suggest some
functional role.
Mapping of the 3′ polyadenylation sites for Pfpcna
and luciferase genes identified three sites that share
consensus sequences with other eukaryotes—a
distinctly different picture when compared to 5′
regions where Plasmodium spp. appear to lack any
homology to cis-acting sequences present in other
eukaryotes.16 The three AATAAmotifs, each closely
followed by a U/GU-rich region within 20–40 bp,
are identical with the only other polyadenylation
sites functionally characterized in P. falciparum,
those of pfs25.43 The functions of these sites in
pfs25, however, were only established in a heterol-
ogous transfection system using the chicken malar-
ial parasite P. gallinaceum.43 Here we have shown
that these consensus polyadenylation sequences
operate, as expected, in a homologous transfection
system, and we have demonstrated further their
fundamental “all-or-nothing” role in maintaining
transcript stability.
Perhaps the most important finding of this study,
however, was that while our genetic deletion and
HDAC inhibitor studies show that we can affect the
absolute level of Pfpcna expression, no effect on the
temporal control of Pfpcna expression was achieved.
While the temporal control of a transfected reporter
217Gene Expression in P. falciparumcassette does rely on appropriate nucleosome
assembly,27,28 a detailed analysis of the role of
histone modifications in directing this temporal
control still remains to be established.17,57 Here we
addressed whether sublethal doses of the HDAC
inhibitors SAHA and SBHA could induce a tran-
scriptional permissive state in any other part of IDC
development, and specifically whether the temporal
repression of Pfpcna expression in ring stages could
be released. While able to demonstrate effects on
IDC progression, induction of morphology typical
of PCD, and failure for reinvasion, which are all
established effects of HDAC treatment, we found no
evidence for an altered temporal profile of Pfpcna
expression—this in spite of using two different
drugs at two different concentrations and inducting
treatment at two different points during the IDC.
Together, these findings suggest that temporal
control of Pfpcna expression during the IDC is not
solely mediated by either genetic elements adjacent
to the promoter or epigenetic factors—both of
which, however, are important mechanisms for the
control of the absolute level of expression. So how
then is temporal expression of Pfpcna controlled?
Recent data from three published studies, taken
together with the data shown here, suggest that
posttranscriptional mechanisms may drive the
temporal expression of Pfpcna. These published
studies indicate the following: (i) a global program
of RNA polymerase II activation during the IDC,
with the peak of activity in mature trophozoites
coinciding with the replication of the genomic
template;58 (ii) a similarly global program of the
increasing stability of mRNA transcripts during IDC
progression;15 and (iii) key components of the
preinitiation complex poised on promoters through-
out the IDC.59 Thus, in ring-stage parasites, where
Pfpcna has been demonstrated to have a low level
of promoter activity and the mRNA transcript has
been demonstrated to have a short half-life
(2.55 min),6,15,36 these mechanisms together would
account for the low steady-state levels of tran-
script and the low level of protein expressed. In
mature trophozoites, Pfpcna promoter activity has
been shown to dramatically increase in line with
the known global activation of RNA polymerase II
at this stage of the IDC, which, together with
the dramatic increase in mRNA stability (half-
life, between 53.4 min and 78.3 min), would
account for the high steady-state mRNA levels and
the corresponding increased levels in protein
expression.6,15,36
We suggest that deletion of Pfpcna 5′ flanking
distal elements prevents the binding of trans-acting
factors that recruit and/or stabilize preinitiation
complex formation. EMSA using ring and tropho-
zoite nuclear extracts indicates that probes 2, 3, and 7
bind a nuclear trans-acting factor (Fig. S7), data that
support an apparent pre-initiation complex (PIC)formation throughout the IDC. The “all-or-nothing”
effect of the deletion of the polyadenylation sites in
pΔ6 and pΔ7 is presumably accounted for by the
role that these sequences play in mediating mRNA
stability. Thus, while the genetic and epigenetic
factors investigated here could readily account for
altered absolute levels of activity, none would
overcome the global mechanisms operating at the
level of RNA polymerase II activity and mRNA
stability. While apparently a novel means to drive
the temporal cascade of gene expression during the
IDC, recent evidence has suggested that P. falciparum
RNA polymerase II is an intrinsically novel
protein,60 exhibiting previously unreported intra-
species plasticity in the number and composition of
its carboxy-terminal repeats governing the plethora
of RNA-polymerase-II–mediated activities. These
finding support a fundamental role for posttran-
scriptional mechanisms in governing the temporal
expression of potentially hundreds of genes during a
stage of parasite development responsible for the
etiology of this devastating disease.Materials and Methods
Transfection constructs
All luciferase reporter cassettes were replaced as ApaI-PstI
fragments into a similarly restricted pDC1600crtGFPAttP
plasmid (a kind gift of D. Fidock, Columbia University,
New York, NY), replacing the existing green fluorescent
protein reporter construct.33 The original Pfpcna luciferase
reporter cassette pPLH121 was modified to generate an
intermediate plasmid, pmPLP1, where the luciferase gene
was flanked by 1418 bp of 5′ flanking sequence and 647 bp
of 3′ flanking sequence from Pfpcna (PF13_0328). Here the
Pfpcna 5′ flanking sequence ismodified by the addition of a
unique 8-bp sequence tag, consisting of the NotI restriction
site 840 bp upstream of the luciferase gene, to differentiate
this sequence from that flanking the endogenous gene. An
ApaI-PstI fragment from pmPLP1 was subcloned into the
pDCAttP host plasmid to generate plasmid Δ1.
The 5′ deletion series was prepared by PCR upstream of
the NotI sequence tag to incorporate 1200 bp (Δ2), 1030 bp
(Δ3), and 860 bp (ΔKO) of 5′ flanking sequence (flanked
with unique ApaI and NotI restriction sites to facilitate
ligation) into iterations of the pmPLP1 plasmid and then
subcloned into the pDCAttP plasmid. The 3′ deletion
plasmids were generated by PCR over a unique EcoRV site
at the 3′ end of the luciferase gene in pmPLP1 to generate
products containing 130 bp (Δ4), 350 bp (Δ5), 494 bp (Δ6),
and 591 bp (Δ7) of the Pfpcna 3′ flanking sequence. These
were directly cloned back into EcoRV-PstI-restrictedΔ1. A
detailed subcloning protocol is available in Fig. S2.P. falciparum culture and transfection
The AHE1 clone (Dd2attB) of P. falciparum was provided
by D. Fidock.33 This is a clone of Dd2 where the attB site
218 Gene Expression in P. falciparumfor mycobacteriophage bxb1 integration into the genome
of M. smegmatis has been inserted into the cg6 locus of
chromosome 7. The presence of this site is maintained by
5 nM WR99210 drug selection. Parasite cultures were
maintained as previously described using successive
treatment with 5% sorbitol61 to maintain synchronization.
Staging and parasitemia of parasite cultures were con-
firmed by light microscopy of Giemsa-stained thin blood
smears. Parasitemia was determined by the proportion of
infected erythrocytes from a count of 1000–2000 erythro-
cytes, with staging determined from a count of at least 200
infected erythrocytes. Transfections of P. falciparum and
subsequent drug selection were carried out as described
by Nkrumah et al. using 40 μg each of the appropriate
luciferase reporter plasmid and the pINT plasmid
(encoding the bxb1 integrase protein). At least two
independent clones for each plasmid were prepared.
Isolation and size fractionation of genomic DNA and
RNA were carried out as previously described.62,63
5′ and 3′ RACE
Parasite RNA (1 μg) from trophozoite-stage parasites
was used for first-strand cDNA synthesis for both 5′ and 3′
RACE protocols. The 5′ RACE-RLM™ System kit (Invi-
trogen) was used, according to the manufacturer's
instructions, with first-strand cDNA synthesis from the
GSP1 primer (5′-TCAAAAGTTATTTTTAAAGATA-
TAAAT GATAATGTGC-3′) located 542 bp upstream of
the luciferase open reading frame. Nested PCR on the first-
strand cDNAwas then performed using the first GSP2 (5′-
TTTATAAATGTTTCTTAATGTATAACTTATGTG-3′)
and then GSP3 (5′-AAATCAAAATGATAAAGCGG-
CCGC-3′) with the supplied 5′ RACE system AUAP
primer. The use of GSP3 targeted to the NotI sequence tag
ensured amplification only of the 5′ end of the luciferase
mRNA. 3′ RACE was performed, using the GeneRacer™
kit (Invitrogen) according to the manufacturer's instruc-
tions, with first-strand cDNA synthesis from an oligo(dT)
primer. Nested PCR on the first-strand cDNA was carried
out for both luciferase and Pfpcna transcripts using pairs of
primers designed at the 3′ ends of each open reading
frame and the supplied 3′ GeneRacer™ primer (Invitro-
gen) and GeneRacer™ nested primer (Invitrogen): Lucout
(5′-CGAAGTACCGAAAGGTCTTACCGG-3′) and Lucin
(5′-AGGCCAAGAAGGGCGGAAAGTCC-3′), Pfpcnaout
(5′-AACATTTTAGCAGATGTCGTTGTCTTAGG-3′) and
Pfpcnain (5′-GATACCTCCCCTGATTCAGATTCAGA-
TACC-3′), where the second primer (Xin) represents the
oligonucleotide used in the nested PCR. 5′ and 3′ RACE
products were subcloned into the pCRII-Blunt-TOPO®
vector (Invitrogen) and sent for commercial sequencing
(Eurofins Mwg). Sequence comparisons were carried out
using ClustalN†.
Luciferase assays
A standard luciferase assay protocol based on previous
protocols21 was followed using a commercially available
Luciferase Assay kit (Promega). For each assay, two 100-μl†http://srs.ebi.ac.uksamples of packed infected erythrocytes were removed
from synchronized P. falciparum culture at approximately
1% parasitemia. Parasites were isolated by lysis in 1×
phosphate-buffered saline/0.1% saponin and subjected to
freeze–thaw lysis in the supplied reporter lysis buffer. Five
microliters of the cleared supernatant was added to 50 μl
of the supplied luciferase substrate reagent assay, and
luciferase activity was measured using the LumiCount™
(Packard) apparatus controlled using PlateReader™ ver-
sion 3 (Packard). All data are reported as arbitrary light
units per 1×107 parasites, and the mean of at least five
pairs of independent experiments was analyzed using
one-way analysis of variants on MiniTab version 14.IC50 determination
IC50 determination was carried out as described by
Desjardins et al.,64 as modified by Bennett et al.65 Stocks
(10 mM) of SAHA and SBHA (kind gifts of K. Andrews,
Queensland Institute of Medical Research) were prepared
in dimethyl sulfoxide, and a serial 3-fold dilution was
carried out on a 96-well plate starting from an initial well
concentration of 100 μM. P. falciparum culture was added
to each well to give a 2% final initial parasitemia at 2%
hematocrit. The plates were incubated for 48 h in a
humidified incubator flushed every 24 h with 1% oxygen,
3% CO2, and 96% nitrogen. Growth inhibition was
assessed by SYBR I green incorporation and plotted as a
percentage of growth against untreated parasites (100%),
and P. falciparum culture was exposed to a supralethal
dose of artemether (0%). Data from two independent
plates containing triplicate wells for each treatment were
analyzed using GraphPad Prism (version 5) software to
determine the IC50 concentration from the sigmoidal
dose–response curve.Electrophoretic mobility shift assays
Nuclear proteins were isolated using a modified
procedure of the protocol published by Lanzer et al.66
First, cytosolic proteins were extracted using the NE-
PER® (Pierce) nuclear and cytoplasmic extraction reagents
according to the manufacturer's instructions. Protein
extraction of the nuclei pellet was performed using low-
salt buffer to remove excess cytosolic proteins, followed by
high-salt buffer upon incubation on ice, releasing nuclear
proteins from the nuclei. The integrity of the nuclear
protein extracts was confirmed by polyacrylamide gel
electrophoresis and Coomassie blue staining. Protein
content was measured using the NanoDrop1000 (Thermo
Scientific). Five micrograms of nuclear extract was
incubated in 20 μl of 1× EMSA binding buffer [20 mM
Hepes (pH 7.9), 10 mM NaCl, 5 mM MgCl, 1 mM
dithiothreitol, 0.25 mg/ml bovine serum albumin, and 5%
glycerol] containing 500 ng of poly(dAdT) as nonspecific
double-stranded competitor DNA, 50 fmol of single-
stranded oligonucleotide probe (N18), and 1× Halt™
Protease Inhibitor Cocktail (Pierce) for 10 min at room
temperature prior to addition of 2.5 fmol of γ-[32P] end-
radiolabeled double-stranded oligonucleotide probes and
incubation for 15 min at room temperature. Reactions
were size-fractionated on 6% polyacrylamide gels in 0.5%
Tris/borate/EDTA and exposed to a phosphor screen for
219Gene Expression in P. falciparumup to 2 days. The image was captured using the Cyclone
storage phosphor screen apparatus (Packard) and ana-
lyzed using the OptiQuant software (Packard). For
competition experiments, the nuclear extract was incubat-
ed with varying molar excess of unlabeled double-
stranded oligonucleotide probe (homologous or heterolo-
gous) for 10 min in binding buffer before the addition of
the labeled probe and further incubation for 15 min at
room temperature. A probe designed against the known
gbp130 (PF10_0159) PfTBP binding site (5′-TTATATTAT-
GAATAAATGTAA GCAGAAAAGGAATGGTGT) was
used as a positive control.44 Signal intensity analysis was
performed on Photoshop CS3 following discarding of
color data to leave a gray-scale image. The mean intensity
value of a defined region was captured, normalized
against the background, and plotted using Prism Graph-
Pad (version 5).
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